Mauro Krampera

List of Publications by Year
in descending order

143	11,647	47006	28297
papers	citations	47	105
		h-index	g-index

144	144	144	14993
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 2003, 101, 3722-3729.	1.4	1,483
2	Role for Interferon-Î³ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem Cells. Stem Cells, 2006, 24, 386-398.	3.2	1,226
3	Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCTÂ®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 2019, 21, 1019-1024.	0.7	466
4	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	4.6	430
5	Toll-Like Receptors 3 and 4 Are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling. Stem Cells, 2008, 26, 279-289.	3.2	429
6	International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy, 2016, 18, 151-159.	0.7	400
7	Adipose-Derived Mesenchymal Stem Cells Ameliorate Chronic Experimental Autoimmune Encephalomyelitis. Stem Cells, 2009, 27, 2624-2635.	3.2	370
8	Immunological characterization of multipotent mesenchymal stromal cellsâ€"The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy, 2013, 15, 1054-1061.	0.7	364
9	Mesenchymal stromal cell â€˜licensingâ€™: a multistep process. Leukemia, 2011, 25, 1408-1414.	7.2	325
10	Human Bone Marrow and Adipose Tissue Mesenchymal Stem Cells: A User's Guide. Stem Cells and Development, 2010, 19, 1449-1470.	2.1	297
11	Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone, 2006, 39, 678-683.	2.9	280
12	Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. Scientific Reports, 2016, 6, 24120.	3.3	262
13	Mesenchymal stem cells for clinical application. Vox Sanguinis, 2010, 98, 93-107.	1.5	228
14	Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus. Bone, 2007, 40, 382-390.	2.9	216
15	HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. Blood, 2005, 106, 59-66.	1.4	210
16	Neuronal Differentiation Potential of Human Adipose-Derived Mesenchymal Stem Cells. Stem Cells and Development, 2008, 17, 909-916.	2.1	205
17	Clinical-Grade Mesenchymal Stromal Cells Produced Under Various Good Manufacturing Practice Processes Differ in Their Immunomodulatory Properties: Standardization of Immune Quality Controls. Stem Cells and Development, 2013, 22, 1789-1801.	2.1	186
18	Toll-Like Receptor-3-Activated Human Mesenchymal Stromal Cells Significantly Prolong the Survival and Function of Neutrophils. Stem Cells, 2011, 29, 1001-1011.	3.2	185

#	Article	IF	Citations
19	Regenerative and immunomodulatory potential of mesenchymal stem cells. Current Opinion in Pharmacology, 2006, 6, 435-441.	3.5	162
20	Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. British Journal of Cancer, 2015, 112, 1067-1075.	6.4	158
21	In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. Stem Cells Translational Medicine, 2015, 4, 1199-1213.	3.3	131
22	Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrowâ€“derived mesenchymal stromal cells. Blood, 2011, 118, 380-389.	1.4	116
23	Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene, 2008, 27, 2542-2551.	5.9	114
24	Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell Stem Cell, 2021, 28, 1708-1725.	11.1	114
25	Stem molecular signature of adipose-derived stromal cells. Experimental Cell Research, 2008, 314, 603-615.	2.6	109
26	Immune Regulation by Mesenchymal Stem Cells Derived from Adult Spleen and Thymus. Stem Cells and Development, 2007, 16, 797-810.	2.1	108
27	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	4.1	106
28	Nestin- and Doublecortin-Positive Cells Reside in Adult Spinal Cord Meninges and Participate in Injury-Induced Parenchymal Reaction. Stem Cells, 2011, 29, 2062-2076.	3.2	102
29	Mesenchymal stem cells and autoimmune diseases. Best Practice and Research in Clinical Haematology, 2011, 24, 49-57.	1.7	100
30	Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Molecular Cancer, 2010, 9, 273.	19.2	99
31	Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. Blood Cancer Journal, 2012, 2, e73-e73.	6.2	91
32	Comparative Study of Immune Regulatory Properties of Stem Cells Derived from Different Tissues. Stem Cells and Development, 2013, 22, 2990-3002.	2.1	89
33	Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia. Oncotarget, 2016, 7, 21713-21727.	1.8	85
34	Neural Stem Cell Niches in Health and Diseases. Current Pharmaceutical Design, 2012, 18, 1755-1783.	1.9	82
35	Mesenchymal stem cells: from biology to clinical use. Blood Transfusion, 2007, 5, 120-9.	0.4	82
36	Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog. Cancer Biology and Medicine, 2017, 14, 109.	3.0	81

#	Article	IF	Citations
37	Signaling pathways in breast cancer: Therapeutic targeting of the microenvironment. Cellular Signalling, 2014, 26, 2843-2856.	3.6	79
38	Mesenchymal stromal cellsâ€™ role in tumor microenvironment: involvement of signaling pathways. Cancer Biology and Medicine, 2017, 14, 129.	3.0	74
39	Extracellular Vesicles Mediate Mesenchymal Stromal Cell-Dependent Regulation of B Cell PI3K-AKT Signaling Pathway and Actin Cytoskeleton. Frontiers in Immunology, 2019, 10, 446.	4.8	73
40	Comparison of Epithelial Differentiation and Immune Regulatory Properties of Mesenchymal Stromal Cells Derived from Human Lung and Bone Marrow. PLoS ONE, 2012, 7, e35639.	2.5	67
41	Meninges: from protective membrane to stem cell niche. American Journal of Stem Cells, 2012, 1, 92-105.	0.4	66
42	The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. Cytotherapy, 2015, 17, 125-127.	0.7	64
43	Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2003, 120, 74-79.	2.5	56
44	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia, 2021, 35, 787-795.	7.2	56
45	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
46	Novel stem/progenitor cells with neuronal differentiation potential reside in the leptomeningeal niche. Journal of Cellular and Molecular Medicine, 2009, 13, 3195-3208.	3.6	54
47	Management of Chronic Myeloid Leukemia in Advanced Phase. Frontiers in Oncology, 2019, 9, 1132.	2.8	54
48	Immune Modulation by Mesenchymal Stem Cells. Transfusion Medicine and Hemotherapy, 2008, 35, 194-204.	1.6	48
49	Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease. Stem Cells, 2020, 38, 698-711.	3.2	48
50	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36, 1870-1878.	7.2	47
51	Immune Regulatory Properties of CD117^{pos} Amniotic Fluid Stem Cells Vary According to Gestational Age. Stem Cells and Development, 2015, 24, 132-143.	2.1	46
52	Intracellular cytokine profile of cord blood T-, and NK- cells and monocytes. Haematologica, 2000, 85, 675-9.	3.5	46
53	Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. Cytotherapy, 2021, 23, 368-372.	0.7	45
54	Meninges harbor cells expressing neural precursor markers during development and adulthood. Frontiers in Cellular Neuroscience, 2015, 9, 383.	3.7	44

#	Article	IF	Citations
55	Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment?. Blood, 2011, 118, 6506-6514.	1.4	43
56	Role of mesenchymal stromal cell-derived extracellular vesicles in tumour microenvironment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 192-198.	7.4	43
57	MSCs: science and trials. Nature Medicine, 2013, 19, 812-812.	30.7	41
58	Inhibition of Notch Signaling Enhances Chemosensitivity in B-cell Precursor Acute Lymphoblastic Leukemia. Cancer Research, 2019, 79, 639-649.	0.9	41
59	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer Journal, 2021, 11, 4.	6.2	41
60	Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large Bâ€cell lymphoma of the central nervous system â€“ an international study of feasibility and efficacy in routine clinical practice. British Journal of Haematology, 2020, 189, 879-887.	2.5	41
61	Immunological properties of embryonic and adult stem cells. World Journal of Stem Cells, 2010, 2, 50.	2.8	40
62	Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 596079.	3.7	35
63	Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential. Cytotherapy, 2020, 22, 602-605.	0.7	35
64	Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells). PLoS ONE, 2017, 12, e0172430.	2.5	35
65	Mesenchymal Stem Cell Biodistribution, Migration, and HomingIn Vivo. Stem Cells International, 2014, 2014, 1-2.	2.5	34
66	Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. International Journal of Obesity, 2018, 42, 334-343.	3.4	31
67	The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche. Frontiers in Cell and Developmental Biology, 2020, 8, 599276.	3.7	30
68	HS-5 and HS-27A Stromal Cell Lines to Study Bone Marrow Mesenchymal Stromal Cell-Mediated Support to Cancer Development. Frontiers in Cell and Developmental Biology, 2020, 8, 584232.	3.7	28
69	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	5.2	28
70	Stem cells to restore insulin production and cure diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 583-600.	2.6	26
71	Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica, 2006, 91, 1109-12.	3.5	26
72	COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review. World Journal of Virology, 2021, 10, 312-325.	2.9	25

#	Article	IF	Citations
73	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. Cancers, 2020, 12, 2913.	3.7	24
74	Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome. European Journal of Haematology, 2020, 105, 468-475.	2.2	21
75	Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia. Cancers, 2019, 11, 1958.	3.7	20
76	Efficacy Assessment of Interferon-Alphaâ€“Engineered Mesenchymal Stromal Cells in a Mouse Plasmacytoma Model. Stem Cells and Development, 2011, 20, 709-719.	2.1	19
77	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2021, 193, 356-368.	2.5	19
78	Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. Oncotarget, 2017, 8, 86987-87001.	1.8	18
79	A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type Î³ in chronic myeloid leukemia patients. Journal of Hematology and Oncology, 2017, 10, 129.	17.0	17
80	Immunophenotypic analysis of hematopoiesis in patients suffering from Shwachmanâ€“Bodianâ€“Diamond Syndrome. European Journal of Haematology, 2015, 95, 308-315.	2.2	16
81	Injection Molded Polymeric Micropatterns for Bone Regeneration Study. ACS Applied Materials & Interfaces, 2015, 7, 7273-7281.	8.0	15
82	Effects of a Ceramic Biomaterial on Immune Modulatory Properties and Differentiation Potential of Human Mesenchymal Stromal Cells of Different Origin. Tissue Engineering - Part A, 2015, 21, 767-781.	3.1	15
83	Tumor Microenvironment Uses a Reversible Reprogramming of Mesenchymal Stromal Cells to Mediate Pro-tumorigenic Effects. Frontiers in Cell and Developmental Biology, 2020, 8, 545126.	3.7	15
84	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. Hematological Oncology, 2020, 38, 372-380.	1.7	15
85	Consensus International Council for Commonality in Blood Banking Automationâ€“International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. Cytotherapy, 2021, 23, 1060-1063.	0.7	15
86	Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. Leukemia Research, 2018, 74, 75-79.	0.8	14
87	Small Molecule Inhibitors of Microenvironmental Wnt/Î²-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia. Cancers, 2020, 12, 2696.	3.7	14
88	Regulative Loop between Î²-catenin and Protein Tyrosine Receptor Type Î³ in Chronic Myeloid Leukemia. International Journal of Molecular Sciences, 2020, 21, 2298.	4.1	14
89	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer, 2021, 127, 2657-2665.	4.1	14
90	The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment. Cancers, 2020, 12, 3757.	3.7	13

#	Article	IF	Citations
91	The serological prevalence of SARSâ€CoVâ€2 infection in patients with chronic myeloid leukemia is similar to that in the general population. Cancer Medicine, 2021, 10, 6310-6316.	2.8	13
92	Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. Oncotarget, 2018, 9, 14219-14227.	1.8	13
93	MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. Oncotarget, 2018, 9, 29753-29771.	1.8	13
94	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. Blood, 2018, 132, 4277-4277.	1.4	11
95	Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53. Oncotarget, 2017, 8, 11809-11826.	1.8	11
96	MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget, 2018, 9, 19961-19979.	1.8	11
97	Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. Critical Reviews in Oncology/Hematology, 2021, 163, 103377.	4.4	10
98	Imatinib-treated Chronic Myeloid Leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. Haematologica, 2015, 100, e299-301.	3.5	9
99	Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma. Frontiers in Oncology, 2020, 10, 600025.	2.8	9
100	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematological Oncology, 2021, 39, 409-418.	1.7	9
101	Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway. Oncotarget, 2018, 9, 18341-18350.	1.8	9
102	High-throughput analysis and functional interpretation of extracellular vesicle content in hematological malignancies. Computational and Structural Biotechnology Journal, 2020, 18, 2670-2677.	4.1	8
103	VR09 Cell Line: An EBV-Positive Lymphoblastoid Cell Line with In Vivo Characteristics of Diffuse Large B Cell Lymphoma of Activated B-Cell Type. PLoS ONE, 2012, 7, e52811.	2.5	7
104	The transcriptional profile of adipose-derived stromal cells (ASC) mirrors the whitening of adipose tissue with age. European Journal of Cell Biology, 2022, 101, 151206.	3.6	7
105	Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. British Journal of Haematology, 2021, 193, 845-848.	2.5	6
106	Emerging data supporting stromal cell therapeutic potential in cancer: reprogramming stromal cells of the tumor microenvironment for anti-cancer effects. Cancer Biology and Medicine, 2020, 17, 828-841.	3.0	6
107	Effects of CD20 antibodies and kinase inhibitors on Bâ€cell receptor signalling and survival of chronic lymphocytic leukaemia cells. British Journal of Haematology, 2021, 192, 333-342.	2.5	5
108	Interferon regulatory factor 7 impairs cellular metabolism with age in adipose-derived stromal cells. Journal of Cell Science, 2021, 134, .	2.0	5

#	Article	IF	Citations
109	Comparison Between Bone Marrow Mesenchymal Stromal Cells (BM-MSC) and Lung Mesenchymal Stromal Cells (Lung-MSC) For Epithelial Regeneration. Blood, 2013, 122, 5414-5414.	1.4	5
110	Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools. Targeted Oncology, 2021, 16, 823-838.	3.6	5
111	CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients. Annals of Hematology, 2019, 98, 2339-2346.	1.8	4
112	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. HemaSphere, 2020, 4, e395.	2.7	4
113	Update on the Role and Utility of Extracellular Vesicles in Hematological Malignancies. Stem Cells, 2022, 40, 619-629.	3.2	4
114	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 2019, 37, 418-423.	1.7	3
115	Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies. Transfusion and Apheresis Science, 2021, 60, 103105.	1.0	3
116	Prognostic impact of <scp>KMT2Aâ€AFF1</scp>â€positivity in 926 <scp>BCRâ€ABL1</scp>â€negative Bâ€lineage acute lymphoblastic leukemia patients treated in <scp>GIMEMA</scp> clinical trials since 1996. American Journal of Hematology, 2021, 96, E334-E338.	4.1	3
117	Prognostic Impact of Notch Signaling in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 5242-5242.	1.4	3
118	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. Blood, 2020, 136, 43-44.	1.4	2
119	Role of Wnt/Î²-Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy. Blood, 2016, 128, 2753-2753.	1.4	2
120	Prognostic Impact of t(4;11)(q21;q23)/KMT2A-AFF1-Positivity in 926 BCR-ABL1-Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996. Blood, 2019, 134, 1469-1469.	1.4	2
121	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4174-4174.	1.4	2
122	Primary sphenoid lymphoma: Focus on imaging. Tumori, 2018, 104, NP42-NP45.	1.1	1
123	Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?. Tumori, 2020, 106, 424-426.	1.1	1
124	Genomic Analysis Of Notch Mutations In a Case Of Alagille Syndrome With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 4992-4992.	1.4	1
125	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4184-4184.	1.4	1
126	BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC". Blood, 2020, 136, 9-10.	1.4	1

#	Article	IF	Citations
127	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. Blood, 2020, 136, 17-18.	1.4	1
128	Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study). Blood, 2020, 136, 42-42.	1.4	1
129	Mesenchymal Stem Cell Isolation and Expansion Methodology. , 2012, , 23-33.		0
130	Mesenchymal Stem/Stromal Cell Trafficking and Homing. , 2017, , 169-191.		0
131	P53 and p21waf1â€" Expression by Immunohistochemistry in Diffuse Large B-Cell Lymphoma Has a Strong and Independent Impact on Survival of Patients with Germinal Center Phenotype.. Blood, 2005, 106, 1920-1920.	1.4	0
132	Quality Controls of Immune Regulatory Properties of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells for Clinical Use (European multicenter study CASCADE),. Blood, 2011, 118, 4049-4049.	1.4	0
133	Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study. Blood, 2016, 128, 5434-5434.	1.4	0
134	CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations. Blood, 2016, 128, 3122-3122.	1.4	0
135	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. Blood, 2018, 132, 3052-3052.	1.4	0
136	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. Blood, 2019, 134, 4166-4166.	1.4	0
137	Comorbidities Reduce Response to Induction Treatment and Survival in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. Blood, 2019, 134, 2587-2587.	1.4	0
138	Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study. Blood, 2019, 134, 5909-5909.	1.4	0
139	Bendamustine plus rituximab: is it a BRIGHT idea?. Chinese Clinical Oncology, 2020, 9, 22-22.	1.2	0
140	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. Blood, 2020, 136, 23-25.	1.4	0
141	Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results. Blood, 2020, 136, 37-38.	1.4	0
142	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. Blood, 2020, 136, 49-50.	1.4	0
143	First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. Blood, 2020, 136, 43-44.	1.4	0